This article is more than 5 years old. Information may no longer be current.
Sanofi Pasteur releases dengue vaccine results
Click Here to Manage Email Alerts
Sanofi Pasteur recently announced the success of its dengue vaccine candidate. Phase 3 study results show the vaccine significantly reduced dengue disease cases among Asian children, according to a press release.
The study included 10,275 children aged 2 to 14 years from Indonesia, Malaysia, Thailand, Vietnam and the Philippines. Participants were randomly assigned to three injections of the vaccine or a placebo every 6 months for 2 years. Researchers found that the vaccine reduced 56% of dengue cases. A long-term follow-up of the study cohort is planned.
The study is the first of two large-scale studies. The second will be conducted in Latin America during the third quarter of 2014. The second study cohort will consist of 20,000 volunteers from Brazil, Colombia, Honduras, Mexico and Puerto Rico.
“This is the first time ever a dengue vaccine successfully completed a phase 3 efficacy study. These significant clinical results, associated with the good safety profile of the vaccine, bring real hope to more than 100 million people affected each year by dengue, a disease without any specific treatment today,” MariaRosario Z. Capeding, MD, of the Research Institute for Tropical Medicine in the Philippines, said in the release.
For more information:
ClinicalTrials.gov, NCT01373281. Accessed May 1, 2014.